Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $501000.0.

  • Janux Therapeutics' Depreciation & Amortization (CF) fell 176.47% to $501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 28.86%. This contributed to the annual value of $2.1 million for FY2024, which is 537.08% up from last year.
  • As of Q3 2025, Janux Therapeutics' Depreciation & Amortization (CF) stood at $501000.0, which was down 176.47% from $541000.0 recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Depreciation & Amortization (CF) peaked at $541000.0 during Q2 2025, and registered a low of $9000.0 during Q1 2021.
  • For the 5-year period, Janux Therapeutics' Depreciation & Amortization (CF) averaged around $343684.2, with its median value being $471000.0 (2023).
  • As far as peak fluctuations go, Janux Therapeutics' Depreciation & Amortization (CF) skyrocketed by 260000.0% in 2021, and later crashed by 357.82% in 2024.
  • Janux Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $64000.0 in 2021, then soared by 529.69% to $403000.0 in 2022, then soared by 31.76% to $531000.0 in 2023, then dropped by 3.58% to $512000.0 in 2024, then decreased by 2.15% to $501000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $501000.0 in Q3 2025, compared to $541000.0 in Q2 2025 and $519000.0 in Q1 2025.